Loss of Interleukin-13-Receptor-Alpha-1 Induces Apoptosis and Promotes EMT in Pancreatic Cancer.
EMT
cytokines
interleukin 13
interleukin 4
interleukin-13-receptor-alpha-1
pancreatic cancer progression
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Mar 2022
26 Mar 2022
Historique:
received:
03
02
2022
revised:
24
03
2022
accepted:
25
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
In search of new therapies for pancreatic cancer, cytokine pathways have attracted increasing interest in recent years. Cytokines play a vital role in the crosstalk between tumour cells and the tumour microenvironment. The related inflammatory cytokines IL-4 and IL-13 can regularly be detected at increased levels in the microenvironment of pancreatic cancer. They share a receptor heterodimer consisting of IL-4Rα and IL-13Rα1. While IL-4Rα induces a more oncogenic phenotype, the role of IL-13Rα1 was yet to be determined. ShRNA-based knockdown of IL-13Rα1 was performed in Capan-1 and MIA PaCa-2. We assessed cell growth and migratory capacities under the influence of IL-13Rα1. Pathway alterations were detected by immunoblot analysis. We now have demonstrated that the loss of IL-13Rα1 induces apoptosis in pancreatic cancer cells. This was associated with an epithelial-to-mesenchymal transition. Loss of IL-13Rα1 also abolished the effects of exogenous IL-4 and IL-13 stimulation. Interestingly, in wild type cells, cytokine stimulation caused a similar increase in migratory capacities as after IL-13Rα1 knockdown. Overall, our results indicate the vital role of IL-13Rα1 in the progression of pancreatic cancer. The differential expression of IL-4Rα and IL-13Rα1 has to be taken into account when considering a cytokine-targeted therapy in pancreatic cancer.
Identifiants
pubmed: 35409019
pii: ijms23073659
doi: 10.3390/ijms23073659
pmc: PMC8998778
pii:
doi:
Substances chimiques
Cytokines
0
IL13RA1 protein, human
0
Interleukin-13
0
Interleukin-13 Receptor alpha1 Subunit
0
Interleukin-4
207137-56-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : China Scholarship Council
ID : 201806090357
Références
J Immunol. 2019 Nov 1;203(9):2532-2544
pubmed: 31548328
Cancer Discov. 2019 Feb;9(2):282-301
pubmed: 30366930
Cent Eur J Immunol. 2019;44(2):190-200
pubmed: 31530989
Int J Mol Sci. 2020 Oct 03;21(19):
pubmed: 33022971
Oncogene. 2014 Jun 19;33(25):3256-66
pubmed: 23912451
Cancer Res. 2002 Jul 1;62(13):3575-80
pubmed: 12097255
Biomed Khim. 2019 Aug;65(5):424-431
pubmed: 31666416
J Hematol Oncol. 2019 Feb 26;12(1):20
pubmed: 30808369
Genes Dev. 1999 Nov 15;13(22):2905-27
pubmed: 10579998
Sci Signal. 2015 Nov 10;8(402):ra114
pubmed: 26554818
Annu Rev Immunol. 1999;17:701-38
pubmed: 10358772
Sci Rep. 2019 Feb 27;9(1):2924
pubmed: 30814616
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Colorectal Dis. 2009 Jan;24(1):57-67
pubmed: 18758789
Cancer Discov. 2020 Apr;10(4):608-625
pubmed: 32046984
Oncol Rep. 2020 Aug;44(2):637-649
pubmed: 32467989
Front Immunol. 2019 Nov 13;10:2638
pubmed: 31798581
Int J Mol Sci. 2017 Mar 28;18(4):
pubmed: 28350325
Int Rev Immunol. 1998;17(1-4):1-52
pubmed: 9914942
Semin Cancer Biol. 2021 Nov;76:232-246
pubmed: 34062264
Cytokine. 2015 Sep;75(1):68-78
pubmed: 26070934
Immunity. 2019 Apr 16;50(4):832-850
pubmed: 30995502
Br J Cancer. 2005 Mar 14;92(5):921-8
pubmed: 15714203
J Cancer. 2017 Feb 25;8(5):761-773
pubmed: 28382138
Neuro Oncol. 2010 Aug;12(8):871-81
pubmed: 20511192
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Cancer Discov. 2020 Oct;10(10):1566-1589
pubmed: 32703770
Oncotarget. 2016 Sep 20;7(38):61183-61198
pubmed: 27533463
J Radiat Res. 2020 May 22;61(3):376-387
pubmed: 32100006
J Clin Oncol. 2015 Dec 1;33(34):4039-47
pubmed: 26351344
Cancer Res. 2012 Dec 15;72(24):6338-43
pubmed: 23222300
Breast Cancer Res. 2003;5(1):31-6
pubmed: 12559043
Cell Signal. 2002 May;14(5):381-95
pubmed: 11882383
Acta Biomater. 2020 Jan 1;101:43-68
pubmed: 31518706
Anticancer Res. 1999 Jan-Feb;19(1A):125-31
pubmed: 10226533
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
J Allergy Clin Immunol. 2020 Aug;146(2):367-376.e3
pubmed: 32407835
Genome Med. 2016 May 03;8(1):38
pubmed: 27137215
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
Cancer Immunol Immunother. 2017 Nov;66(11):1485-1496
pubmed: 28733709
Acta Microbiol Immunol Hung. 2015 Dec;62(4):341-78
pubmed: 26689873
Drug Saf. 2018 May;41(5):489-509
pubmed: 29411337
Int J Mol Sci. 2021 Mar 15;22(6):
pubmed: 33804263
Oncotarget. 2017 Aug 3;8(48):83370-83383
pubmed: 29137350